Previous 10 | Next 10 |
Gainers: Alder BioPharmaceuticals (NASDAQ: ALDR ) +84% . SemGroup Corporation (NYSE: SEMG ) +63% . Yuma Energy (NYSEMKT: YUMA ) +63% . Wins Finance Holdings (NASDAQ: WINS ) +55% . Whiting Petroleum Corporation (NYSE: WLL ) +43% . New Concept Energy (NYSEMKT: GBR ) +34% . Califo...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that it has been added to the Russell 2000 ® and 3000 ® indexes effective September...
Gainers: Francesca's Holdings (NASDAQ: FRAN ) +92% . Mallinckrodt plc (NYSE: MNK ) +64% . Pier 1 Imports (NYSE: PIR ) +41% . YRC Worldwide (NASDAQ: YRCW ) +32% . Endo International (NASDAQ: ENDP ) +29% . Dean Foods Company (NYSE: DF ) +28% . Basic Energy Services (NYSE: BAS ) ...
In recent years, mountains of institutional capital have flowed into hundreds of biotech start-ups and so many of them have gone public that it's impossible for anyone with a day job to keep track of them all. I'll let you in on a little secret. Those of us paid to know things about the biophar...
Dravet syndrome is a severe and progressive genetic epilepsy generally caused by mutations in the SCN1A gene The BUTTERFLY study is designed to evaluate seizure frequency and non-seizure comorbidities; data will support clinical development plans for the company’s lead therapeut...
Stoke Therapeutics (NASDAQ: STOK ): Q2 GAAP EPS of -$1.54 misses by $0.58 . More news on: Stoke Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2019. “We are making efficient and meani...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its le...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the ...
Point Roberts, WA and Delta, BC - July 19, 2019 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week's additions to its global stock directories in biotech, tech and defense. This week's new additions are all recent Nasdaq IPO...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...